Most population-based cohort researches indicated that antirheumatic treatment may not exactly be associated with the cancer recurrence risk in RA patients, either in those receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic DMARDs (bDMARDs) [31, 34–38] like tumor necrosis factor (TNF) [39–42], and a few studies found that using bDMARDs reduced the overall risk of acquiring malignancies except for hematologic malignancies [43]. This evidence concerns the gene TNF and hematologic disorder.